Tumor necrosis factor–inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor–driven model of rheumatoid arthritis
Authors:
- Antonia PuchnerAPAntonia Puchner
- Birgit NiederreiterBNBirgit Niederreiter
- Silvia HayerSHSilvia Hayer
- Harald LeissHLHarald Leiss
- Stephan BlümlSBStephan Blüml
- Roman KreindlRKRoman Kreindl
- Kurt RedlichKRKurt Redlich
Open Access
- 28 December 2012
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (3) , 608-617
Abstract
Objective: To investigate how tumor necrosis factor (TNF)–inhibiting therapy affects bone destruction and inflammation in a TNF‐driven mouse model of rheumatoid arthritis.Methods: In order to evaluate the influence of TNF on osteoclastogenesis in vitro, different concentrations of TNF were added to spleen cell–derived monocytes in the absence or presence of different concentrations of RANKL. In addition, the effects of TNF inhibition on osteoclast precursors as well as local bone destruction in vivo were assessed by treating TNF‐transgenic mice with different doses of adalimumab.Results: TNF stimulated osteoclastogenesis mainly by increasing the number of osteoclast precursor cells in vitro. This TNF effect was independent of the presence of RANKL. In the hTNF‐transgenic mouse model of destructive arthritis, low‐dose TNF‐inhibiting therapy with adalimumab had no effect on synovial inflammation but significantly inhibited local bone destruction and the generation of osteoclasts. This inhibition was accompanied by a reduction in the number of c‐Fms–positive osteoclast precursor cells in the bone marrow and a reduction of the osteoclast precursor pools in the blood and inflamed synovial membrane of hTNF‐transgenic mice.Conclusion: Low‐dose TNF‐inhibiting therapy significantly reduces bone erosions by reducing the number of circulating and joint‐invading osteoclast precursors. This effect is uncoupled from its antiinflammatory action.Keywords
This publication has 34 references indexed in Scilit:
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destructionAnnals of the Rheumatic Diseases, 2012
- Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximabAnnals of the Rheumatic Diseases, 2010
- Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritisArthritis & Rheumatism, 2010
- Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1Proceedings of the National Academy of Sciences, 2008
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Arthritis Research & Therapy, 2008
- TNF-induced structural joint damage is mediated by IL-1Proceedings of the National Academy of Sciences, 2007
- High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatmentArthritis & Rheumatism, 2002
- A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and FunctionBiochemical and Biophysical Research Communications, 1999
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- DIFFERENCE IN CARTILAGE PROTEOGLYCAN LEVEL IN SYNOVIAL FLUID IN EARLY RHEUMATOID ARTHRITIS AND REACTIVE ARTHRITISThe Lancet, 1985